文献速递肾小球疾病

霉酚酸酯联合激素治疗C3肾小球病:病例系列

Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-01-11

该回顾性病例系列纳入30例C3肾小球病患者,接受霉酚酸酯联合激素治疗至少3个月并随访至少1年。67%患者达到缓解,基线蛋白尿较低和可溶性膜攻击复合物水平较高与缓解相关,停药后复发率50%,该方案优于其他免疫抑制方案。

要点

  • 霉酚酸酯联合激素可使67%的C3肾小球病患者获得缓解。
  • 基线蛋白尿较低和可溶性膜攻击复合物水平较高与治疗敏感相关。
  • 停用霉酚酸酯后复发率达50%,需关注维持治疗策略。

核心结论

  • 在耐受霉酚酸酯的患者中,联合激素治疗使67%的队列获得缓解。
  • 治疗开始时蛋白尿较重和可溶性膜攻击复合物水平较低与治疗抵抗相关。

研究设计与样本

  • 回顾性图表审查,来自哥伦比亚大学C3肾小球病登记,纳入30例接受霉酚酸酯至少3个月并随访至少1年的患者。

主要发现

  • 中位年龄25岁(IQR 18-36),中位肌酐1.07 mg/dl(IQR 0.79-1.69),中位蛋白尿3200 mg/g肌酐(IQR 1720-6759)。
  • 中位随访32个月(IQR 21-68),20例(67%)为缓解者。
  • 缓解者初始蛋白尿中位2468 mg/g肌酐,低于非缓解者的5000 mg/g肌酐;缓解者可溶性膜攻击复合物水平高于非缓解者。
  • 停用霉酚酸酯者复发率为50%。
  • 全基因组补体基因分析发现12例患者携带18个预测有害变异,均未报道为致病性。

临床怎么用

  • 对于耐受霉酚酸酯的C3肾小球病患者,可考虑霉酚酸酯联合激素治疗。
  • 基线蛋白尿较重和可溶性膜攻击复合物水平较低提示可能治疗抵抗,需密切监测。
  • 停用霉酚酸酯后复发风险高,应个体化制定维持和撤药策略。

局限性

  • 回顾性病例系列,样本量小(30例),无对照组,结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: C3 glomerulopathy is a form of complement-mediated GN. Immunosuppressive therapy may be beneficial in the treatment of C3 glomerulopathy. Mycophenolate mofetil is an attractive treatment option given its role in the treatment of other complement-mediated diseases and the results of the Spanish Group for the Study of Glomerular Diseases C3 Study. Here, we study the outcomes of patients with C3 glomerulopathy treated with steroids and mycophenolate mofetil. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective chart review of patients in the C3 glomerulopathy registry at Columbia University and identified patients treated with mycophenolate mofetil for at least 3 months and follow-up for at least 1 year. We studied clinical, histologic, and genetic data for the whole group and compared data for those who achieved complete or partial remission (responders) with those who did not achieve remission (nonresponders). We compared remission with mycophenolate mofetil with remission with other immunosuppressive regimens. RESULTS: We identified 30 patients who met inclusion criteria. Median age was 25 years old (interquartile range, 18-36), median creatinine was 1.07 mg/dl (interquartile range, 0.79-1.69), and median proteinuria was 3200 mg/g creatinine (interquartile range, 1720-6759). The median follow-up time was 32 months (interquartile range, 21-68). Twenty (67%) patients were classified as responders. There were no significant differences in baseline characteristics between responders and nonresponders, although initial proteinuria was lower (median 2468 mg/g creatinine) in responders compared with nonresponders (median 5000 mg/g creatinine) and soluble membrane attack complex levels were higher in responders compared with nonresponders. For those tapered off mycophenolate mofetil, relapse rate was 50%. Genome-wide analysis on complement genes was done, and in 12 patients, we found 18 variants predicted to be damaging. None of these variants were previously reported to be pathogenic. Mycophenolate mofetil with steroids outperformed other immunosuppressive regimens. CONCLUSIONS: Among patients who tolerated mycophenolate mofetil, combination therapy with steroids induced remission in 67% of this cohort. Heavier proteinuria at the start of therapy and lower soluble membrane attack complex levels were associated with treatment resistance.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Avasare RS, Canetta PA, Bomback AS, et al. Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series. Clin J Am Soc Nephrol. 2018. PMID: 29326307. doi:10.2215/CJN.09080817

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。